Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RBP4 | P02753 | 2/20 | 0.61 |
| ▸ | HTT | P42858 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | CNR1 | P21554 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | PKLR | P30613 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3223484 | 0.88 | HTR2A (0.53) | RBP4HTTLMNASMN1; SMN2PKM | |
| SCHEMBL3205601 | 0.87 | HSD11B1 (0.57) | RBP4LMNAHSD11B1KDM4ECNR1 | |
| SCHEMBL3205508 | 0.86 | KMT2A (0.54) | RBP4HSD11B1KDM4EGAAHPGD | |
| SCHEMBL3201836 | 0.83 | LMNA (0.60) | RBP4HTTLMNASMN1; SMN2HSD11B1 | |
| SCHEMBL3219555 | 0.83 | HSD11B1 (0.64) | RBP4LMNASMN1; SMN2HSD11B1KMT2A | |
| SCHEMBL3221289 | 0.81 | HSD11B1 (0.64) | RBP4LMNAHSD11B1GAAKMT2A | |
| SCHEMBL3215762 | 0.81 | GPR183 (0.53) | RBP4HSD11B1KDM4ECYP2C19GAA | |
| SCHEMBL3209386 | 0.81 | HSD11B1 (0.55) | RBP4HTTLMNAHSD11B1PKM | |
| SCHEMBL3225759 | 0.81 | RBP4 (0.46) | RBP4HSD11B1KDM4EHPGDKMT2A | |
| SCHEMBL1471495 | 0.81 | TP53 (0.62) | HTTLMNASMN1; SMN2HSD11B1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029648-A1 | 11-Beta HSD1 Inhibitors | XIANG JASON SHAOYUN | 2010-02-04 | — | — | US | disclosed |
| US-7632838-B2 | 11-beta HSD1 inhibitors | WYETH (US) | 2009-12-15 | — | — | US | disclosed |
| US-20070219198-A1 | 11-Beta HSD 1 inhibitors | WYETH (US) | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029648-A1 | 11-Beta HSD1 Inhibitors | HSD11B1, HSD3B1, HSD11B2 | RBP4 2175/4885HTT 1959/4885LMNA 3748/4885 |
| US-20070219198-A1 | 11-Beta HSD 1 inhibitors | HSD11B1, HSD11B2, HSD3B1 | RBP4 2329/4885HTT 1640/4885LMNA 3681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.